Enzon Pharmaceuticals (ENZN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ENZN Stock Summary
- For ENZN, its debt to operating expenses ratio is greater than that reported by only 0.52% of US equities we're observing.
- With a price/sales ratio of 716.55, ENZON PHARMACEUTICALS INC has a higher such ratio than 99.43% of stocks in our set.
- As for revenue growth, note that ENZN's revenue has grown -95.89% over the past 12 months; that beats the revenue growth of merely 1.01% of US companies in our set.
- Stocks that are quantitatively similar to ENZN, based on their financial statements, market capitalization, and price volatility, are PFBX, UIHC, HALL, NRIM, and CHMG.
- Visit ENZN's SEC page to see the company's official filings. To visit the company's web site, go to www.enzon.com.
ENZN Valuation Summary
- ENZN's EV/EBIT ratio is 35.3; this is 305.75% higher than that of the median Healthcare stock.
- Over the past 243 months, ENZN's EV/EBIT ratio has gone up 20.2.
Below are key valuation metrics over time for ENZN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ENZN | 2022-12-02 | 703.4 | 7.4 | -7.2 | 35.3 |
| ENZN | 2022-12-01 | 703.4 | 7.4 | -7.2 | 35.3 |
| ENZN | 2022-11-30 | 703.4 | 7.4 | -7.2 | 35.3 |
| ENZN | 2022-11-29 | 703.4 | 7.4 | -7.2 | 35.3 |
| ENZN | 2022-11-28 | 689.7 | 7.3 | -7.0 | 35.8 |
| ENZN | 2022-11-25 | 717.2 | 7.5 | -7.3 | 34.8 |
ENZN Growth Metrics
- The year over year revenue growth rate now stands at -25.75%.
- The year over year cash and equivalents growth rate now stands at -1.57%.
- Its 4 year net income to common stockholders growth rate is now at 24.51%.
The table below shows ENZN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 0.029 | -1.039 | -2.852 |
| 2022-06-30 | 0.029 | -1.397 | -3.038 |
| 2022-03-31 | 0.32 | -0.758 | -2.819 |
| 2021-12-31 | 0.701 | -0.501 | -2.492 |
| 2021-09-30 | 0.706 | -0.796 | -2.638 |
| 2021-06-30 | 0.714 | -0.794 | -2.313 |
ENZN Stock Price Chart Interactive Chart >
ENZN Price/Volume Stats
| Current price | $0.28 | 52-week high | $0.48 |
| Prev. close | $0.28 | 52-week low | $0.24 |
| Day low | $0.28 | Volume | 9,666 |
| Day high | $0.28 | Avg. volume | 40,933 |
| 50-day MA | $0.27 | Dividend yield | N/A |
| 200-day MA | $0.31 | Market Cap | 20.60M |
Enzon Pharmaceuticals (ENZN) Company Bio
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron and Sylatron. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Latest ENZN News From Around the Web
Below are the latest news stories about ENZON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ENZN as an investment opportunity.
7 Undervalued Biotech Stocks to Buy Before They BoomSpeculative investors should consider building a position in these undervalued biotech stocks before the market rebounds. |
ENZN Price Returns
| 1-mo | 4.48% |
| 3-mo | -4.44% |
| 6-mo | -2.44% |
| 1-year | -27.31% |
| 3-year | 33.33% |
| 5-year | 344.44% |
| YTD | -18.25% |
| 2021 | 37.88% |
| 2020 | 20.58% |
| 2019 | 284.33% |
| 2018 | -6.78% |
| 2017 | -26.00% |
Continue Researching ENZN
Here are a few links from around the web to help you further your research on Enzon Pharmaceuticals Inc's stock as an investment opportunity:Enzon Pharmaceuticals Inc (ENZN) Stock Price | Nasdaq
Enzon Pharmaceuticals Inc (ENZN) Stock Quote, History and News - Yahoo Finance
Enzon Pharmaceuticals Inc (ENZN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...